U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07245251) titled 'To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004' on Nov. 17.
Brief Summary: This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia.
Study Start Date: Dec. 03
Study Type: INTERVENTIONAL
Condition:
Acute Lymphobkastic Leukemia
Intervention:
DRUG: STR-P004
This study enrolls adult patients with B-cell acute lymphoblastic leukemia (B-ALL). Enroll...